Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies
Chronic myeloid leukemia (CML) / Posted 1 year ago
Brief Summary
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
Detailed Description
Part A ( for Healthy volunteers) of the study is completed
Part B dose-escalation study is completed. Recruitment in dose-expansion is ongoing in India and Korea
Part C study in subjects with treatment-refractory/intolerant is enrolling globally.
-
Inclusion Criteria :
- Accepts Healthy Volunteers: No
- Willing and able to give written, and dated, informed consent
- Male or female aged ≥ 18 years
- Willing and able to comply with the scheduled visits
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Subjects diagnosed with Ph+ CML-CP, Ph+ CML-AP, Ph+ CML-BP, who are resistant and/or intolerant to ≥ 3 prior TKIs one of which includes ponatinib (Part C).
-
Exclusion Criteria :
- Presence of T315I (PART C)
- Any major surgery, as determined by the Investigator, within 4 weeks of IMP administration
- Inability to undergo venipuncture and/or tolerate venous access
- Positive exclusion tests: urine pregnancy tests (if applicable), HIV, hepatitis B surface antigen, or hepatitis C virus
- Known or suspected history of significant drug abuse as judged by the Investigator
- Received any other investigational agent within 30 days or a washout of at least 5 half-lives, whichever is longer of IMP administration
- Subjects who are eligible for potentially curative therapy that is available, including hematopoietic stem cell transplant
- Another primary malignancy within the past 3 years or earlier (except for adequately treated non-melanoma skin cancer or cervical cancer in situ
- Study start date : April 25, 2017
- Study end date : August 2026
- Wales-Based Study Contact : Please speak to your clinician
- Principal Investigator : de Lavallade Hugues (King's College Hospital)